The vision for collaborative progress in European rare disease research

Although individually rare, taken together, rare diseases affect at least 20 million people in Europe, representing a major issue in healthcare. Research to tackle rare diseases can be fragmented, so innovative efforts to increase collaboration and coordination are vital if we are to advance our understanding and develop new diagnostics and therapies.

By Dr Ritchie Head

The EU has a strong commitment to rare disease research to improve the lives of patients. I’ve seen this over the course of my work managing several projects part-funded within their drive to address rare disease in Europe. I manage VISION DMD, an important collaborative project for Duchenne Muscular Dystrophy (DMD). It’s part of a portfolio of projects funded by the EU. This project adopted a venture philanthropy model that has been a crucial element in the project successfully completing a clinical trial for a new steroid-like drug for DMD called vamorolone.

As rare diseases individually affect fewer people, it’s especially crucial to bring people, policy and funding thinking together across countries. So when I recently had the opportunity to talk to Dr. Daria Julkowska, Scientific Coordinator of the European Joint Program on Rare Diseases (EJP RD), I jumped at the chance. Since its launch in 2019, the EJP RD has been critical to reducing fragmentation and accelerating research collaborations. It is creating a comprehensive, sustainable ecosystem, allowing a virtuous circle between research, care and medical innovation, and pools resources at national and European level at a scale never achieved before.

Dr. Julkowska is an innovative leader in the EU rare disease landscape, having recently won the Black Pearl European Rare Disease Leadership Award. Her team has pulled together research funders, universities, research organisations and infrastructures, hospitals and patient organisations from more than 135 institutions in 35 countries.

We spoke about the challenges and successes of coordinating across vast networks, diverse stakeholder groups and through layers of EU infrastructure. We touched on the role of data-sharing to drive progress, and on the particular dedication of the rare disease community. Of course, we also spoke about why this work is so important – to drive the participation and influence of patient groups, and ultimately get the science out of the lab and into real life, where it can save and improve lives. 

Ultimately, she told me: "our goal is that diagnosis, care and treatment should all be available within one year of a rare disease patient coming to medical attention – and we hope to achieve this by 2027”.

Read the full interview here.

 

 

 

Innovation & Research Strategy

Innovation & Research Strategy

We bring independent thinking and insight to help clients develop and refine excellent research proposals and business plans...

FIND OUT MORE

Funding

Funding

We have been successful in multiple EU and UK funding applications and can provide help and advice about the suitability of your research plans for National and European...

FIND OUT MORE

Project Management

Project Management

Successful projects require a focused approach to project management. Our experienced professionals can provide management support to...

FIND OUT MORE

Communication

Communication

Scientific advances influence almost all parts of society, so scientists and the research community have a duty to communicate research results...

FIND OUT MORE

Exploitation & Impact

Exploitation & Impact

Demonstrating the impact of research is now critical to modern projects and forms a key criterion of proposal evaluation...

FIND OUT MORE

Training

Training

Our aim is to help you understand grant funding, learn the key elements of a winning proposal and how to manage a collaborative project...

FIND OUT MORE